The FDA on October 14, 2020 extended the approval of KEYTRUDA® (Pembrolizumab) for the following indications:
1) Adult patients with Relapsed or Refractory classical Hodgkin Lymphoma (cHL)
2) Pediatric patients with Refractory cHL, or cHL that has Relapsed after 2 or more lines of therapy.
KEYTRUDA® is a product of Merck Sharp & Dohme Corp.
